Passage Bio, Inc.PASGNASDAQ
Loading
R&D Expense Growth AcceleratingAccelerating
Percentile Rank75
3Y CAGR+20.0%
5Y CAGR-5.4%
Year-over-Year Change
Year-over-year research & development expense growth
3Y CAGR
+20.0%/yr
vs -36.6%/yr prior
5Y CAGR
-5.4%/yr
Recent acceleration
Acceleration
+56.6pp
Accelerating
Percentile
P75
Within normal range
vs 5Y Ago
0.8x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 25.80% |
| Q3 2025 | -25.92% |
| Q2 2025 | -24.85% |
| Q1 2025 | -19.05% |
| Q4 2024 | 10.42% |
| Q3 2024 | -17.01% |
| Q2 2024 | -9.58% |
| Q1 2024 | -5.15% |
| Q4 2023 | -19.45% |
| Q3 2023 | -12.85% |
| Q2 2023 | 2.90% |
| Q1 2023 | -4.65% |
| Q4 2022 | 14.94% |
| Q3 2022 | -42.72% |
| Q2 2022 | 2.32% |
| Q1 2022 | -22.83% |
| Q4 2021 | 27.59% |
| Q3 2021 | -19.60% |
| Q2 2021 | 32.61% |
| Q1 2021 | -10.60% |
| Q4 2020 | 34.05% |
| Q3 2020 | 4.70% |
| Q2 2020 | 51.73% |
| Q1 2020 | 31.54% |
| Q4 2019 | -4.43% |
| Q3 2019 | 65.65% |
| Q2 2019 | 107.68% |
| Q1 2019 | -48.95% |
| Q4 2018 | 0.00% |